Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry

Anouk Jochems; Monique K. van der Kooij; Marta Fiocco; Maartje G. Schouwenburg; Maureen J. Aarts; Alexander C. van Akkooi; Franchette W. P. J. van den Berkmortel; Christian U. Blank; Alfonsus J. M. van den Eertwegh; Margreet G. Franken; Janwillem B. de Groot; John B. A. G. Haanen; Geke A. P. Hospers; Rutger H. Koornstra; Wim H. J. Kruit; Marieke Louwman; Djura Piersma; Rozemarijn S. van Rijn; Karijn P. M. Suijkerbuijk; Albert J. ten Tije; Gerard Vreugdenhil; Michel W. J. M. Wouters; Michiel C. T. van Zeijl; Koos J. M. van der Hoeven; Ellen Kapiteijn

doi:10.3390/cancers11071007

Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry

Anouk Jochems
, Monique K. van der Kooij
, Marta Fiocco
, Maartje G. Schouwenburg
, Maureen J. Aarts
, Alexander C. van Akkooi
, Franchette W. P. J. van den Berkmortel
, Christian U. Blank
, Alfonsus J. M. van den Eertwegh
, Margreet G. Franken
, Janwillem B. de Groot
, John B. A. G. Haanen
, Geke A. P. Hospers
, Rutger H. Koornstra
, Wim H. J. Kruit
, Marieke Louwman
, Djura Piersma
, Rozemarijn S. van Rijn
, Karijn P. M. Suijkerbuijk
, Albert J. ten Tije

Gerard Vreugdenhil, Michel W. J. M. Wouters, Michiel C. T. van Zeijl, Koos J. M. van der Hoeven, Ellen Kapiteijn

Department of Medical Oncology, 2300 RC Leiden, Netherlands
Dutch Institute for Clinical Auditing, 2333 AA Leiden, Netherlands
Medical Statistics, 2300 RC Leiden, Netherlands
Mathematical Institute Leiden University, 2333 CA Leiden, Netherlands
Department of Medical Oncology, 6202 AZ Maastricht, Netherlands
Department of Surgical Oncology, 1066 CX Amsterdam, Netherlands
Department of Medical Oncology, 6130 MB Sittard-Geleen, Netherlands
Department of Medical Oncology, 1066 CX Amsterdam, Netherlands
Department of Health Technology Assessment, 3000 DR Rotterdam, Netherlands
Department of Medical Oncology, 8000 GK Zwolle, Netherlands
Department of Medical Oncology, 9713 GZ Groningen, Netherlands
Department of Medical Oncology, 6500 HB Nijmegen, Netherlands
Department of Medical Oncology, 3000 CA Rotterdam, Netherlands
Netherlands Comprehensive Cancer Organisation, 3501 DB Utrecht, Netherlands
Department of Medical Oncology, 7512 KZ Enschede, Netherlands
Department of Medical Oncology, 8934 AD Leeuwarden, Netherlands
Department of Medical Oncology, 3584 CX Utrecht, Netherlands
Department of Medical Oncology, 4819 EV Breda, Netherlands
Department of Medical Oncology, 5500 MB Veldhoven, Netherlands

Research output: Contribution to journal › Article › Academic › peer-review

15 Downloads (Pure)

Abstract

Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.

Original language	English
Article number	1007
Journal	Cancers
Volume	11
Issue number	7
DOIs	https://doi.org/10.3390/cancers11071007
Publication status	Published - 1 Jul 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Metastatic uveal melanoma
Prognostic factor
Survival
Treatment strategy
Uveal melanoma

Access to Document

10.3390/cancers11071007

Metastatic-uveal-melanoma-treatment-strategies-and-survivalresults-from-the-dutch-melanoma-treatment-registry.pdfFinal published version, 2.09 MBLicence: CC BY

Cite this

Jochems, A., van der Kooij, M. K., Fiocco, M., Schouwenburg, M. G., Aarts, M. J., van Akkooi, A. C., van den Berkmortel, F. W. P. J., Blank, C. U., van den Eertwegh, A. J. M., Franken, M. G., de Groot, J. B., Haanen, J. B. A. G., Hospers, G. A. P., Koornstra, R. H., Kruit, W. H. J., Louwman, M., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., ... Kapiteijn, E. (2019). Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry. Cancers, 11(7), Article 1007. https://doi.org/10.3390/cancers11071007

@article{436edf94011a4fd7839767b40b0a73a8,

title = "Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry",

abstract = "Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50\% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95\% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95\%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88\%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36\%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6\% and a GNAQ mutation in 49.2\% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.",

keywords = "Metastatic uveal melanoma, Prognostic factor, Survival, Treatment strategy, Uveal melanoma",

author = "Anouk Jochems and \{van der Kooij\}, \{Monique K.\} and Marta Fiocco and Schouwenburg, \{Maartje G.\} and Aarts, \{Maureen J.\} and \{van Akkooi\}, \{Alexander C.\} and \{van den Berkmortel\}, \{Franchette W. P. J.\} and Blank, \{Christian U.\} and \{van den Eertwegh\}, \{Alfonsus J. M.\} and Franken, \{Margreet G.\} and \{de Groot\}, \{Janwillem B.\} and Haanen, \{John B. A. G.\} and Hospers, \{Geke A. P.\} and Koornstra, \{Rutger H.\} and Kruit, \{Wim H. J.\} and Marieke Louwman and Djura Piersma and \{van Rijn\}, \{Rozemarijn S.\} and Suijkerbuijk, \{Karijn P. M.\} and \{ten Tije\}, \{Albert J.\} and Gerard Vreugdenhil and Wouters, \{Michel W. J. M.\} and \{van Zeijl\}, \{Michiel C. T.\} and \{van der Hoeven\}, \{Koos J. M.\} and Ellen Kapiteijn",

note = "Funding Information: Funding: This specific research manuscript received no external funding. The Netherlands Organization for Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant number: 836002002. This grant was awarded under the effectiveness research for high-cost medicine programme. From its foundation, the DMTR was sponsored by BMS, GSK (later acquired by Novartis), Roche Nederland B.V. and MSD (from 2015) via the Dutch Institute for Clinical Auditing (DICA). Funding Information: Conflicts of Interest: In relation to their contribution to this specific manuscript the authors declare no conflict of interest. Some authors however have consulting/advisory relationships and have received funding for other research projects. A.J. has in the past received travel/ accommodation expenses from Roche BV Netherlands. A.C.v.A. has consulting/advisory relationships with Amgen, BMS, Novartis, MSD and Merck-Pfizer. He has received research funding from Amgen and Novartis and travel, accommodations, and expenses from Amgen and Novartis. C.U.B. has consulting/advisory relationships with BMS, MSD, Roche, Novartis, GSK, Lilly and Pfizer. He has received research funding from Novartis. A.J.M.v.d.E. has consulting/advisory relationships with BMS, Roche, MSD and Novartis. He has received a study grant from R. MargreetG. Franken has received grants from Roche BV Netherlands, Daiichi Sanky, AbbVie, Pamgene and Gilead Sciences. Jan Willem B. de Groot has advisory relationships with BMS, MSD and Roche. J.B.A.G. Haanen has provided consultation, attended advisory boards, and/or provided lectures for MSD, BMS, Roche and Novartis for which NKI received honoraria. His institution has received grant support from BMS and Novartis. G.A.P.H. has consulting/advisory relationships with Roche, MSD, BMS and Novartis. Her institution has received research funding from BMS. RutgerH. Koornstra has received speaker fees from BMS, MSD and Roche. He has advisory relationships with BMS, MSD, Novartis and Roche and has received research grants from BMS and Roche. K.P.M.S. has consulting/advisory relationships with BMS and MSD and has received honoraria from Novartis, Roche and Pierre Fabre (paid to institution). E.K. has consulting/advisory relationships with BMS, Novartis, Roche, Amgen, Pierre Fabre (honoraria paid to institution) and has received research grants from BMS, Novartis. Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = jul,

day = "1",

doi = "10.3390/cancers11071007",

language = "English",

volume = "11",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

Jochems, A, van der Kooij, MK, Fiocco, M, Schouwenburg, MG, Aarts, MJ, van Akkooi, AC, van den Berkmortel, FWPJ, Blank, CU, van den Eertwegh, AJM, Franken, MG, de Groot, JB, Haanen, JBAG, Hospers, GAP, Koornstra, RH, Kruit, WHJ, Louwman, M, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, Vreugdenhil, G, Wouters, MWJM, van Zeijl, MCT, van der Hoeven, KJM & Kapiteijn, E 2019, 'Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry', Cancers, vol. 11, no. 7, 1007. https://doi.org/10.3390/cancers11071007

TY - JOUR

T1 - Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry

AU - Jochems, Anouk

AU - van der Kooij, Monique K.

AU - Fiocco, Marta

AU - Schouwenburg, Maartje G.

AU - Aarts, Maureen J.

AU - van Akkooi, Alexander C.

AU - van den Berkmortel, Franchette W. P. J.

AU - Blank, Christian U.

AU - van den Eertwegh, Alfonsus J. M.

AU - Franken, Margreet G.

AU - de Groot, Janwillem B.

AU - Haanen, John B. A. G.

AU - Hospers, Geke A. P.

AU - Koornstra, Rutger H.

AU - Kruit, Wim H. J.

AU - Louwman, Marieke

AU - Piersma, Djura

AU - van Rijn, Rozemarijn S.

AU - Suijkerbuijk, Karijn P. M.

AU - ten Tije, Albert J.

AU - Vreugdenhil, Gerard

AU - Wouters, Michel W. J. M.

AU - van Zeijl, Michiel C. T.

AU - van der Hoeven, Koos J. M.

AU - Kapiteijn, Ellen

N1 - Funding Information: Funding: This specific research manuscript received no external funding. The Netherlands Organization for Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant number: 836002002. This grant was awarded under the effectiveness research for high-cost medicine programme. From its foundation, the DMTR was sponsored by BMS, GSK (later acquired by Novartis), Roche Nederland B.V. and MSD (from 2015) via the Dutch Institute for Clinical Auditing (DICA). Funding Information: Conflicts of Interest: In relation to their contribution to this specific manuscript the authors declare no conflict of interest. Some authors however have consulting/advisory relationships and have received funding for other research projects. A.J. has in the past received travel/ accommodation expenses from Roche BV Netherlands. A.C.v.A. has consulting/advisory relationships with Amgen, BMS, Novartis, MSD and Merck-Pfizer. He has received research funding from Amgen and Novartis and travel, accommodations, and expenses from Amgen and Novartis. C.U.B. has consulting/advisory relationships with BMS, MSD, Roche, Novartis, GSK, Lilly and Pfizer. He has received research funding from Novartis. A.J.M.v.d.E. has consulting/advisory relationships with BMS, Roche, MSD and Novartis. He has received a study grant from R. MargreetG. Franken has received grants from Roche BV Netherlands, Daiichi Sanky, AbbVie, Pamgene and Gilead Sciences. Jan Willem B. de Groot has advisory relationships with BMS, MSD and Roche. J.B.A.G. Haanen has provided consultation, attended advisory boards, and/or provided lectures for MSD, BMS, Roche and Novartis for which NKI received honoraria. His institution has received grant support from BMS and Novartis. G.A.P.H. has consulting/advisory relationships with Roche, MSD, BMS and Novartis. Her institution has received research funding from BMS. RutgerH. Koornstra has received speaker fees from BMS, MSD and Roche. He has advisory relationships with BMS, MSD, Novartis and Roche and has received research grants from BMS and Roche. K.P.M.S. has consulting/advisory relationships with BMS and MSD and has received honoraria from Novartis, Roche and Pierre Fabre (paid to institution). E.K. has consulting/advisory relationships with BMS, Novartis, Roche, Amgen, Pierre Fabre (honoraria paid to institution) and has received research grants from BMS, Novartis. Publisher Copyright: © 2019 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.

AB - Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.

KW - Metastatic uveal melanoma

KW - Prognostic factor

KW - Survival

KW - Treatment strategy

KW - Uveal melanoma

UR - https://www.scopus.com/pages/publications/85071184407

U2 - 10.3390/cancers11071007

DO - 10.3390/cancers11071007

M3 - Article

C2 - 31323802

SN - 2072-6694

VL - 11

JO - Cancers

JF - Cancers

IS - 7

M1 - 1007

ER -

Metastatic uveal melanoma: Treatment strategies and survival—results from the dutch melanoma treatment registry

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this